Skip to Content

Sales of multiple sclerosis drug Tecfidera helped treat this pharmaceutical firm to a hale 2014 (though recent results missed targets).

Company Information

Location
Cambridge, MA
Industry
Pharmaceuticals
Sector
Health Care
Fortune 500 Rank298
Fortune 500 Profilehttp://fortune.com/fortune500/biogen-298/
Current Streak1
Years on List1
CEO
George A. Scangos
Websitehttp://www.biogen.com

Revenue, Net Income

Revenue Past Four Quarters10,129
Net Income Past Four Quarters3,277

Growth Rates

EPS 3 yr Annual Growth Rate35%
Rev 3 yr Annual Growth Rate26%
Total Return 3 yr Annual Rate41%
Beat S&P 3 yr Total Return?
yes

Rank

EPS Growth Rank69
Revenue Growth Rank63
Total Return Rank
53